Mylan says it doubts a sale to Teva would get regulatory approval; hasn't received offer

Generic drugmaker Mylan, citing media speculation that Teva Pharmaceutical may be eyeing it as a takeover target, says it doubts that regulators would approve such a deal. Mylan says it is committed to its current strategy as a stand-alone company.

In a news release Friday, Mylan said that it hasn't received an offer and described the idea that Teva might want to buy it as a rumor.

The Dutch company says antritrust regulators probably wouldn't approve a deal between Mylan and Teva because their businesses overlap in major ways.

Teva did not immediately respond to a request for comment.

Mylan NV says it would perform due diligence on an offer if it received one.

Earlier this month Mylan offered to buy generic drug and ingredients maker Perrigo for about $29 billion.